Despite recent advancements in therapeutic options, it is still one of the most clinically challenging blood cancers, with a notably low 5-year survival rate of 30% and a high rate of relapse 1,2
Patients who have renal or hepatic disorders dont even need dose modifications
Healthcare providers typically consider the overall benefit-risk profile of a medication when prescribing it to patients
New York : A New Yorker gave Peaka GLP-1 a 2.5 out of 5, citing minimal changes in their condition
Body Protecting Peptide benefits were originally discovered in the 1970s and have become a go-to supplement for many health care providers, particularly in the integrative, naturopathic, and chiropractic space
Based on current clinical guidelines and our patient experience: Strong indication: BMI 30 (obesity) without active contraindications BMI 27 (overweight) with weight-related comorbidities such as hypertension, dyslipidaemia, type 2 diabetes, sleep apnoea, or fatty liver disease Patients who have attempted weight management through diet and exercise without sustained results Patients who have plateaued with other weight management interventions Relative indication (clinical judgement): BMI 25-27 with specific metabolic drivers (pre-diabetes, insulin resistance, PCOS) Patients preparing for weight-related surgery or other medical interventions Patients with specific body composition goals beyond BMI criteria Not indicated or contraindicated: Pregnancy, breastfeeding, or pregnancy planning within next 2 months Personal or family history of medullary thyroid cancer or MEN2 syndrome Personal history of pancreatitis Active severe gastroparesis or severe gastrointestinal disease BMI below 25 (cosmetic use for body contouring in normal-weight individuals is not appropriate) Eating disorder history GLP-1 use can be problematic for patients with restrictive eating patterns Frequently asked questions Is Ozempic "better" for weight loss than Wegovy
